Blood Markers to Predict AML Treatment Response
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at special markers in bone marrow fluid to predict how well chemotherapy will work for newly diagnosed acute myeloid leukemia (AML). By identifying these markers early, doctors may be able to choose the best treatment plan for each patient.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Newly diagnosed with acute myeloid leukemia (AML), not a type called APL
- Have never received chemotherapy before for this disease
- Have a family member who can participate with you in the study
- Able to understand the study and sign consent documents
- No other active cancers requiring treatment
- No serious infections like HIV, hepatitis, or COVID-19
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at a substance called leptin in the blood of people with newly diagnosed acute myeloid leukemia (AML). The goal is to see if leptin levels can help doctors predict how well chemotherapy will work, which could guide better treatment choices.
This trial looks at whether a protein called IL-6 can help predict how well chemotherapy will work in people with acute myeloid leukemia (AML) who haven't been treated before. It aims to find better ways to personalize treatment.
This trial looks at certain chemical changes in blood cells of two groups of people aged 60 or older: those having heart surgery (control group) and those with a type of blood cancer called acute myeloid leukemia (AML) who will be treated with a drug called azacitidine. The goal is to find markers that could help personalize treatment for AML in seniors.
This study looks at markers in the blood to understand why low red blood cell counts (anemia) can cause bleeding problems in people with certain leukemias. It may help find better ways to treat or prevent bleeding during early chemotherapy.
This trial studies whether choosing treatment based on lab test “biomarkers” (specific genetic or blood markers) can help people with acute myeloid leukemia (AML). It focuses on adults who are not good candidates for the most intensive chemotherapy, and it uses different sub-studies for different AML types.
This study looks at certain proteins in the blood (called FLT3 ligand and IL6) of people being treated for blood cancers like AML, MDS, or CMML. The goal is to understand how these proteins change during non-intensive chemotherapy, which may help doctors better personalize treatment.
Hear when a new Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.